Management of end-stage heart disease

著者

書誌事項

Management of end-stage heart disease

editors, Eric A. Rose, Lynne Warner Stevenson

Lippincott-Raven, c1998

大学図書館所蔵 件 / 全8件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

As the number of patients with end-stage heart disease continues to rise, the need for broader, better management guidelines increases. Dr. Rose's practical new book fills that need. All of the standard, time-tested treatment methods -- as well as the most current, cutting-edge alternatives -- are comprehensively covered. You'll find medical therapies that utilize positive inotropic agents, adrenergic blocking agents, and other drugs; surgical options, such as revascularization and valve surgery; myocardial replacement therapies that restore function through ventricular assist devices, flow pumps, and artificial hearts; and myocardial enhancement therapies, including dynamic cardiomyoplasty and ventriculectomy. Sound advice on the economic consequences and future implications of ESHD help you to make the best choices for every patient

目次

  • Part 1 Defining the problem: cardiac replacement - estimation of need, demand and supply, Roger W. Evans
  • economic impact of heart failure, Mark A. Robbins and John B. O'Connell
  • endpoints for evaluation of therapies, Ileana L. Pina, Ross R. Zimmer and Victor Gil. Part 2 Medical therapy for congestive heart failure: approach to the patient with severe heart failure, Gary S. Francis
  • positive inotropic agents in the treatment of heart failure, Rene Alvarez and Arthur Feldman
  • evolution of heart failure treatment - considering adrenergic blocking agents and amiodarone, James B. Young
  • arrhythmias in end-stage heart failure, William G. Stevenson and Michael O. Sweeney
  • permanent pacemaker therapy for improvement of cardiac function in advanced heart failure, Leslie A. Saxon
  • exercise capacity in heart failure - impairment and improvement, Donna M. Mancini
  • when is heart failure a surgical disease?, Lynne Warner Stevenson. Part 3 Conventional surgical options: high-risk myocardial revascularization, John A. Kern and Irving L. Kron
  • ventricular aneurysmectomy and surgical ablative approaches for malignant arrhythmias, Lynda Mickelborough
  • valve surgery in patients with severe left ventricualr dysfunction, Francis D. Pagani and Steven F. Bolling. Myocardial replacement therapies: cardiac allotransplantation, Daniel J. Golstein and Eric A. Rose
  • xenotransplantation, John H. Artrip, Oktavijan P. Minanov, Silviu Itescu, and Robert E. Michler
  • left ventricular assist devices, Michael Argenziano and Mehmet C. Oz
  • total artificial heart, Robert T.V. Kung
  • axial flow pumps. Myocardial enhancement therapies: surgical therapy for heart failure - dynamic cardiomyoplasty, George Magovern Jr, Kathleen A. Simpson, James A. Magovern and George J. Magovern Sr.
  • myocyte transplantation, Cliff van Meter, ventriculectomy, Randas J. Vilela Bastista. Afterword: the future management of end-stage heart disease.

「Nielsen BookData」 より

詳細情報

ページトップへ